Needham initiated a Buy rating for Absci (ABSI), noting its AI-powered drug discovery platforms, strategic partnerships, and ...

BofA Securities made adjustments to its outlook on AMD (NASDAQ:AMD) shares, lowering the price target to $135 from the previous $155, while keeping a Neutral stance on the company. According to ...

The deal is structured as a private investment in a public equity and includes an equity stake in Absci. AMD didn’t disclose the amount of its stake.

"In our view, the ability to generate high quality wet-lab data is critical for advancement," analyst says in initiating ...

AMD collaborates with Absci for AI drug discovery advancements. AMD makes a $20 million investment to boost drug research. Get Wall Street's Hottest Chart Every Morning The partnership will ...

Jan. 08, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, today announced a strategic collaboration with AMD to deploy AMD Instinct ...

Absci Corporation (ABSI) announced a strategic collaboration with AMD (AMD) to deploy AMD Instinct accelerators and ROCm software to power critical AI drug discovery workloads, including Absci’s ...

(RTTNews) - Absci Corporation (ABSI), a Washington-based biotechnology company, Wednesday has announced a strategic collaboration with AMD to deploy AMD Instinct accelerators and ROCm software to ...

The deal is structured as a private investment in a public equity and includes an equity stake in Absci. AMD didn’t disclose the amount of its stake. AMD, which is based in Santa Clara ...

Morningstar brands and products Company Portfolio ...